UBS’s Enzymotec Ltd ENZY Stock Holding History

UBS’s Portfolio ENZY Stock Details ENZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-281	Closed	-$4K	–	11055
2014 Q2	$4K	Sell	281 -1,370	-83%	-$23K	﹤0.01%	9736
2014 Q1	$36K	Sell	1,651 -6,997	-81%	-$185K	﹤0.01%	7295
2013 Q4	$234K	Buy	+8,648	New	+$206K	﹤0.01%	5134

Other funds holding ENZY

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MACM

March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

UBS's ENZY Position: Q3 2014 in Review

UBS sold out of Enzymotec Ltd (ENZY) in Q3 2014, closing a stake of 281 shares — an estimated $4K sold.

UBS first reported a position in ENZY in Q4 2013 and held it in 3 quarters. The position peaked at $234K in Q4 2013. 22 funds tracked by Wall St. Rank hold ENZY as of Q3 2014.

UBS reported no remaining Enzymotec Ltd position as of Q3 2014 after selling out during the quarter.
UBS sold 281 Enzymotec Ltd shares in Q3 2014, an estimated $4K.
UBS first reported a position in Enzymotec Ltd in Q4 2013 and held it in 3 quarters.
UBS's Enzymotec Ltd position peaked at $234K in Q4 2013.
22 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.